FDA OKs Multipathogen Nucleic Acid Test for CNS Infections

  • FDA,Multipathogen Nucleic Acid,CNS
  • medscape

The US Food and Drug Administration (FDA) today approved the first nucleic acid-based test of cerebrospinal fluid (CSF) that can simultaneously detect 14 pathogens responsible for central nervous system (CNS) infections.

The FilmArray Meningitis/Encephalitis (ME) Panel (BioFire Diagnostics) is designed to test CSF specimens from patients who have signs and symptoms of these two conditions. The test can yield results in about 60 minutes. In contrast, it may take up to 3 days to identify a bacterial infection using current diagnostic technology, according to an FDA news release. The wait time for viral infections can be longer, given that specimens often must be shipped to specialized laboratories.

The quicker turnaround with the FilmArray ME Panel, the agency said, "may enable clinicians to make informed treatment decisions earlier."

The FilmArray ME Panel uses a small CSF sample. "Currently, testing CSF for multiple organisms is not always possible because it can be difficult to obtain enough fluid from each patient to run multiple tests," the FDA said.

The new test identifies the following pathogens:

Bacteria and yeast

  • Escherichia coli K1

  • Haemophilus influenzae

  • Listeria monocytogenes

  • Neisseria meningitidis

  • Streptococcus agalactiae

  • Streptococcus pneumoniae

  • Cryptococcus neoformans/gattii


  • Cytomegalovirus

  • Enterovirus

  • Herpes simplex virus 1

  • Herpes simplex virus 2

  • Human herpesvirus 6

  • Human parechovirus

  • Varicella zoster virus

The FDA cautions that the FilmArray ME Panel does not identify all causes of CNS infections or pinpoint which antimicrobial drug may work the best against a bacterial kind. Accordingly, clinicians should still perform standard CSF bacterial and fungal cultures because the new test can produce false negatives and false positives. In addition, bacterial growth is needed for drug susceptibility testing in the case of positive results.

In a prospective study of CSF samples taken from 1560 patients with suspected meningitis or encephalitis, there was "high agreement" between the results from the FilmArray ME Panel and those from other test methods, including culture. The new test also proved accurate in identifying pathogens already known to exist in other CSF samples.

More information on todays announcement is available on the FDA website.

This link:http://www.chemcd.com/news/18904.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus


Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.